Several lines of evidence suggest that the anterior pituitary hormone prolactin has a stimulatory roIe on immune function and that pharmacological suppression of prolactin secretion with the dopamine-agonist bromocriptine suppresses both humoral and cellular immunity. Here, we describe the effects of prolactin-suppression on the course of experimental allergic encephalomyelitis in female Lewis rats. Initiation of continuous bromocriptine treatment before immunization reduced both the severity and incidence of clinical signs of acute experimental allergic encephalomyelitis. Experimental allergic encephalomyelitis-immunized rats experienced a threefold rise in basal prolactin levels on day 4 after immunization and maintained elevated prolactin levels on day 10, before the onset of neurological signs of experimental allergic encephalomyelitis. Bromocriptine treatment reduced prolactin levels to those of shamimmunized rats. In viva bromocriptine pretreatment inhibited splenic lymphocyte proliferative responses in vitro to the immunizing antigen and to concanavalin A. Moreover, bromocriptine therapy was protective when initiated 1 week after the initial immunization and w a s also effective in suppression of late disease. These results indicate that (1) prolactin levels are elevated after immunization and before the onset of experimental allergic encephalomyelitis, (2) bromocriptine inhibits both prolactin secretion and the severity of acute experimental allergic encephalomyelitis, and (3) inhibition is also present when treatment is begun after sensitization, suggesting an effect of prolactin on the effector limb of the immune response during experimental allergic encephalomyelitis.
Several lines of evidence suggest that the anterior pituitary hormone prolactin has a stimulatory roIe on immune function and that pharmacological suppression of prolactin secretion with the dopamine-agonist bromocriptine suppresses both humoral and cellular immunity. Here, we describe the effects of prolactin-suppression on the course of experimental allergic encephalomyelitis in female Lewis rats. Initiation of continuous bromocriptine treatment before immunization reduced both the severity and incidence of clinical signs of acute experimental allergic encephalomyelitis. Experimental allergic encephalomyelitis-immunized rats experienced a threefold rise in basal prolactin levels on day 4 after immunization and maintained elevated prolactin levels on day 10, before the onset of neurological signs of experimental allergic encephalomyelitis. Bromocriptine treatment reduced prolactin levels to those of shamimmunized rats. In viva bromocriptine pretreatment inhibited splenic lymphocyte proliferative responses in vitro to the immunizing antigen and to concanavalin A. Moreover, bromocriptine therapy was protective when initiated 1 week after the initial immunization and w a s also effective in suppression of late disease. These results indicate that (1) prolactin levels are elevated after immunization and before the onset of experimental allergic encephalomyelitis, (2) bromocriptine inhibits both prolactin secretion and the severity of acute experimental allergic encephalomyelitis, and (3) inhibition is also present when treatment is begun after sensitization, suggesting an effect of prolactin on the effector limb of the immune response during experimental allergic encephalomyelitis. Modulation of PRL secretion represents one potential approach to the control of disease states characterized by heightened immune reactivity, including auto- Clinical EAE scores were graded daily by the following standard scoring system: 0, no neurological signs; 1, diminished tone and paresis of the tail; 2, weak hind limbs; 3 , plegic hind limbs; 4, quadriparesis; and 5 , death. A value of 0.5 was added for incontinence. Rats were graded according to the highest single score attained, without addition of scores.
BCR Treatment
Rats were lightly anesthetized with ether for subcutaneous implantation of a single pellet containing either BCR or a control pellet (Innovative Products of America, Toledo, OH). The BCR pellets were designed to continuously release the drug at a rate of 2.3 rng/day for 21 days 141. Control pellets contained the same carrier binder as the BCR pellets (cholesterol, stearate, phosphates, a-lactose, and other proprietary ingredients).
Measurement of Prolactin Levels
Serum PRL levels were measured from trunk blood and from pituitary extracts in duplicate by radioimmunoassay (RIA), using materials provided by the National Institute of Diabetes, Digestive and Kidney Diseases, as previously reported {lo}. Pituitary extracts were prepared by sonicating each pituitary in 1 ml of 0.65 M borate buffer, p H 9.0, centrifugation at 15,000 g for 10 minutes, and decantation of the supernatant. The sensitivity of the RIA is less than 0.25 ng/ml. Intra-assay and interassay coefficients of variation are less than 59%.
Proliferative Assays
Spleens from killed rats (n = 7/group) were aseptically removed and mechanically dispersed. Splenic lymphocytes were pooled and isolated by Ficoll-gradient centrifugation (Pharmacia, Piscataway, NJ). Cells were plated in triplicate in 96-well plates at a concentration of 2 x lo5 cellsiwell, with medium consisting of RPMI 1640 (GIBCO, Grand Island, NY), suppiemented with 5% heat-inactivated fetal calf serum (GIBCO), 1% L-glutarnine, 19% NaPyruvate (GIBCO), 1,25% HEPES buffer (GIBCO), 1% nonessential amino acids, 1% penicillin-streptomycin (GIBCO), and 5 x M 2-mercaptoethanol. Additionally, GPSC (0.19%) or ConA (5 (*g/ml) (Sigma Chemical, St Louis, MO) were included in the medium. After 80 hours of incubation, E3H)thymidine was added for another 16 hours of incubation, cells were harvested, and thymidine incorporation was measured in a scintillation counter. The proliferative response was expressed as counts per minute (cpm), and as stimulation indices (SI), defined as the stimulated culture counts per minute divided by the unstimulated culture counts per minute. The effect on EAE of BCR pellets implanted 2 days before immunization is shown in the Figure and in Table 1 . When compared with dummy-implant controls, BCR treatment reduced both the incidence of signs of EAE ( p < 0.05, Fisher exact probability test) as well as the clinical EAE score ( p < 0.001 MannWhitney U test). Two BCR-treated rats had signs of disease beginning 1 day after exhaustion of the BCR pellet. One of these rats had not had previous clinical signs of EAE.
Results

Bromocriptine
Proliferative studies of splenic lymphocytes harvested from rats killed on day 10 after immunization revealed a pronounced reduction in mitogenic responses both to the immunogen and to ConA in BCRtreated rats (Table 2) .
Immunization was associated with a greater than threefold rise in serum PRL levels ( Table 3) . BCR treatment effectively inhibited this rise in serum and reduced pituitary PRL content measured 10 days after immunization.
Delayed Initiation of Bromocrz$tine Treatment
Moderates Acute and Late Disease BCR pellets implanted 1 week after immunization were also effective in moderating the incidence of signs of acute EAE ( p < 0.01, x2) and the peak clinical EAE score ( p < 0.025, Mann-Whitney U ) ( Table 4) . Additionally, a reduction in the incidence and severity of late disease was found in the BCR-treatment compared with the control-treatment group ( p < 0.025) (see Ta- Acute EAE was assessed in rats in whch BCR or control pellets were implanted 7 or 8 days after immunization Iate disease was assessed in the rats that were treated on day 8 after m u w a t i o n BCR = bromocriptine, EAE = expermental aller@c encephalomyelitis $3 i 0 01, x2 test ble 4). It was again observed that 2 of 8 BCR-treated rats developed signs of late disease beginning 1 and 3 days after exhaustion of the BCR pellet.
Discussion
These results indicate that BCR pretreatment of susceptible Lewis rats resulted in substantial protection from acute EAE, and that protection was associated with a proportional decrease in splenic proliferative responses to both immunogen and to ConA. BCR treatment initiated 1 week after immunization, at a time after sensitization had occurred E l 11, also inhibited acute EAE and, in addition, prevented late disease that typically occurs in female rats during the early recovery period 112, 131. Moreover, signs of EAE developed in several rats after the BCR pellets were exhausted. These results indicate that BCR protection results at least in part from inhibition of the effector limb of the T-cell response in rat EAE.
Protection was incomplete because nearly 50% of BCR-treated, immunized rats developed signs of EAE that were generally mild and consisted of a loss of tail tone or an unsteady gait. It is possible that higher dosages or more effective delivery of BCR might provide more complete inhibition of disease. This is suggested by the finding that suppressed but detectable serum PRL levels were present in BCR-treated rats. Additionally, the effects of BCR on the pathology of EAE at different stages during the disease course is interesting, and these studies are underway.
It is likely that the effects of BCR in rat EAE are Under normal conditions, PRL is secreted episodically, in pulses of varying size and duration, with highest levels during the night in association with sleep 1161. In addition to its underlying diurnal secretory rhythm, PRL is acutely secreted in response to stress E16, 171 . In contrast to the effects of acute stress, chronic stress (or chronic adrenocorticoid treatment) inhibits PRL secretion ElS}. PRL is secreted in large amounts during the postpartum period, and is the most important hormonal stimulus for lactation in mammals [lo, 161. It might be predicted that in immunized animals, "stress" hormones such as adrenocorticotropic hormone and PRL would be erratically stimulated as a result of nonspecific discomfort. Besedovsky and associates El91 and Saphier [201, however, have demonstrated that a coordinated pattern of hypothalamic neurochemical and neuroendocrine events occurs in concert with other aspects of the immune response; for example, hypothalamic noradrenergic activity is inhibited at the peak of the immune response to sheep red blood cells, several days before the rise of plasma corticosterone levels.
Neuroendocrine responses also occur in a stereotypical, predictable pattern in EAE; corticosterone levels rise predictably just before the onset of paralysis, reaching peak levels at the time of maximum neurological disease [ 2 l}. The rise of corticosterone is an essential homeostatic response because adrenalectomized animals invariably die within a few days of immunization. Adrenalectomy soon after the onset of EAE pro-motes EAE relapses 1227, suggesting that release of endogenous glucocorticoids modulates both the initial and the recurrent phases of the disease. In the current experiments, the severity of EAE was reduced in rats implanted with control pellets 1 week after immunization, perhaps due to effects of acute corticosterone secretion imparted by ether anesthesia.
There is little information regarding PRL secretion during immune responses, and thus, the current findings that serum PRL levels are elevated in rat EAE are particularly interesting. One recent report indicated that PRL levels of male rats are stimulated to 150% of control levels during the first 6 days after immunization with CFAIM. bouis [23] . In EAE, the rise in serum PRL. is likely a consequence of immunization and is not disease specific, but further studies will be required to clarify this point. One potential mechanism of PRL stimulation during immune responses involves lymphokine-mediated stimulation of PRL secretion through direct actions on the hypothalamus or pituitary 1241.
In humans, elevated serum PRL levels have been reported to follow cardiac transplantation and to be present in some patients with chronic idiopathic iridocyclitis 125, 261. In the former condition, a high level of circulating PRL was believed to presage graft rejection, and in the latter, a clinical response to BCR has been claimed. Previous studies indicate that there is an increased risk of attacks of multiple sclerosis in the postpartum period, a time of physiological PRL hypersecretion 127-347. Other autoimmune diseases have been observed to occur almost uniquely (e.g., lymphocytic hypophysitis) or more commonly (rheumatoid arthritis and myasthenia gravis) during the puerperium 135, 361. Although the neuroendocrine regulation of immune homeostasis is undoubtedly complex, inhibition of PRL secretion may thus represent a potential approach to the control of autoimmune disorders.
